Get the Stockscreener App
2.87
2.14%
0.06
InspireMD Inc. stock is traded at $2.87, with a volume of 74,263.
It is up +2.14% in the last 24 hours and up +0.35% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$2.81
Open:
$2.85
24h Volume:
74,263
Relative Volume:
1.63
Market Cap:
$74.86M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-2.7333
EPS:
-1.05
Net Cash Flow:
$-16.76M
1W Performance:
+2.14%
1M Performance:
+0.35%
6M Performance:
+5.37%
1Y Performance:
+14.80%
1-Day Range:
$2.7212
$2.90
1-Week Range:
$2.67
$3.34
52-Week Range:
$1.81
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.87 | 74.86M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD, Inc. (NASDAQ:NSPR) Q4 2024 Earnings Call Transcript - Insider Monkey
InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ... By GuruFocus - Investing.com Canada
InspireMD Inc. Reports 2024 Financial Results and Strategic Progress - TipRanks
InspireMD’s Earnings Call: Cautious Optimism Amid Challenges - TipRanks
InspireMD earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Earnings call transcript: InspireMD Q4 2024 beats revenue forecast, stock rises - Investing.com India
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
InspireMD reports Q4 EPS (19c) vs (16c) last year - TipRanks
INSPIREMD Earnings Results: $NSPR Reports Quarterly Earnings - Nasdaq
InspireMD Achieves Record $1.95M Revenue as FDA Approval Nears - StockTitan
InspireMD, Inc. SEC 10-K Report - TradingView
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World
InspireMD (NYSE:NSPR) and Bluejay Diagnostics (NASDAQ:BJDX) Head to Head Survey - Defense World
InspireMD (NYSE:NSPR) Now Covered by StockNews.com - Defense World
InspireMD, Inc. to Host Earnings Call - ACCESS Newswire
InspireMD announces inducement grants under Nasdaq listing rule - MSN
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
When Will InspireMD Release Its 2024 Results? Key Date for Carotid Stent Maker Announced - StockTitan
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is InspireMD's Hiring Spree a Signal for Investors? Company Awards 138K Shares to New Talent - StockTitan
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years - Yahoo Finance
InspireMD and NAMSA to begin study of carotid stent system for TCAR procedures - Yahoo
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com - Defense World
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal - GlobeNewswire
InspireMD And NAMSA To Partner On CGuardians II Pivotal Clinical Trial Of The CGuard Prime 80 Cm Carotid Stent System For Use In TCAR Procedures - Marketscreener.com
Major Clinical Trial Alert: InspireMD's Revolutionary TCAR Stent Targets $1B+ Market - StockTitan
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - Defense World
Key Executive Compensation Alert: InspireMD Awards Strategic Stock Package to New Hire - StockTitan
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 86%, even after 10% gain this past week - Simply Wall St
Compliance Issues And Stock Developments Hit Nasdaq Companies - Evrim Ağacı
InspireMD Awards Strategic Employee Stock Grants to Accelerate Growth, Adds 9 New Hires - StockTitan
StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD : Breakthrough device in clinical trials aims to prevent strokes -January 20, 2025 at 07:59 am EST - Marketscreener.com
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation - Yahoo Finance
InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com - MarketBeat
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
InspireMD, Inc. CFO Craig Shore to Retire, Company Initiates Search for SuccessorDecember 12, 2024 - Defense World
NSPRInspireMD, Inc. Latest Stock News & Market Updates - StockTitan
Medical device company kicks off search for next CFO - The Business Journals
InspireMD CFO Craig Shore to retire, successor search underway - Investing.com India
InspireMD CFO Retirement Amid Strategic Transition - TipRanks
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):